Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axon Presented Positive Phase II Trial Results of AADvac1 at AAT-AD\/PD 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"CYPRUS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axon Neuroscience Has a Promising Peptide Vaccine Against COVID-19 in Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CYPRUS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AXON Neuroscience Presented Results from its Phase II Clinical Trial Showing Multifold Therapeutic Effect of its Vaccine-Induced Antibodies at Eurotau 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"CYPRUS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Axon Neuroscience

    Menu

    Axon Neuroscience

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Axon Neuroscience

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Cyprus
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AXON Neuroscience Presented Results from its Phase II Clinical Trial Showing Multifold Therapeutic Effect of its Vaccine-Induced Antibodies at Eurotau 2021

              Details:

              Axon is developing AADvac1 as a vaccine with the potential to halt the progression of tau pathology in Alzheimer's disease. AADvac1 is currently the most clinically-advanced tau immonotherapy in development.

              Lead Product(s): AADvac1

              Therapeutic Area: Neurology Product Name: AADvac1

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 01, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Axon Neuroscience

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Cyprus
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Axon Neuroscience Has a Promising Peptide Vaccine Against COVID-19 in Development

              Details:

              Axon used its established peptide-based vaccine platform to produce a novel prophylactic COVID-19 vaccine, intended to treat infected patients and protect healthy individuals from infection.

              Lead Product(s): COVID-19 peptide vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 09, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Axon Neuroscience

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Cyprus
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Axon Presented Positive Phase II Trial Results of AADvac1 at AAT-AD/PD 2020

              Details:

              A highly significant impact on neurodegeneration was shown on brain proteins in plasma - Neurofilament Light Chain, and CSF - Tau and p-Tau, and Diffusion Tensor Imaging.

              Lead Product(s): AADvac1

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 03, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY